                         SEQUENCE LISTING

<110>  Novo Nordisk A/S
 
<120>  GLP-1 receptor agonist compounds with a modified N-terminus

<130>  8304.204-WO

<160>  3     

<170>  PatentIn version 3.5

<210>  1
<211>  29
<212>  PRT
<213>  Homo sapiens


<220>
<221>  PEPTIDE
<222>  (1)..(28)

<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Without the two N-terminal amino acid residues His-Ala of 
       hGLP-1(7-37)

<400>  1

Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala 
1               5                   10                  15      


Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly 
            20                  25                  


<210>  2
<211>  37
<212>  PRT
<213>  Heloderma suspectum


<220>
<221>  PEPTIDE
<222>  (1)..(37)

<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Without the two N-terminal amino acid residues of His-Gly of 
       exendin-4(1-39)

<400>  2

Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala 
1               5                   10                  15      


Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly 
            20                  25                  30          


Ala Pro Pro Pro Ser 
        35          


<210>  3
<211>  35
<212>  PRT
<213>  Xenopus laevis


<220>
<221>  PEPTIDE
<222>  (1)..(35)

<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Without the two N-terminal amino acid residues His-Ala og GLP-1A

<400>  3

Glu Gly Thr Phe Thr Ser Asp Val Thr Gln Gln Leu Asp Glu Lys Ala 
1               5                   10                  15      


Ala Lys Glu Phe Ile Asp Trp Leu Ile Asn Gly Gly Pro Ser Lys Glu 
            20                  25                  30          


Ile Ile Ser 
        35  


